false
0001759186
0001759186
2024-12-03
2024-12-03
0001759186
us-gaap:CommonStockMember
2024-12-03
2024-12-03
0001759186
us-gaap:WarrantMember
2024-12-03
2024-12-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
FORM 8-K
_____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported):
December 3, 2024
_____________________
COEPTIS THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its
charter)
Delaware |
001-39669 |
98-1465952 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification No.) |
|
|
|
105 Bradford Rd, Suite 420
Wexford, Pennsylvania |
|
15090 |
(Address of principal executive offices) |
|
(Zip Code) |
724-934-6467
(Registrant’s telephone number, including area code)
____________________________________________________________
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common Stock, par value $0.0001 per share |
|
COEP
|
|
Nasdaq
Capital Market |
Warrants,
each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share |
|
COEPW |
|
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
On December 3, 2024, Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP)
(“Coeptis”) issued a press release announcing the entering into of a letter of intent with NexGenAI Holding Group Inc. for
the acquisition by Coeptis of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates (“NexGenAI”)
that offers AI-powered marketing software and robotic process automation (“RPA”) capabilities. The closing of this transaction
is subject to preparation and execution of definitive documents. A copy of the press
release is included with the Current Report on Form 8-K.
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Coeptis Therapeutics Holdings, Inc. |
|
|
|
Date: December 4, 2024 |
By: |
/s/ David Mehalick |
|
|
David Mehalick
Chief Executive Officer |
Exhibit 99.1
Coeptis Therapeutics
Executes Binding Letter of Intent to Acquire
AI-Powered Marketing
Solutions for Biotech, Pharmaceutical and Other Industries
The Acquisition of NexGenAI Affiliates Network
Expands Company’s Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth
WEXFORD, PA., December 3, 2024 -- - Coeptis Therapeutics Holdings,
Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms
for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent for the acquisition
of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates (“NexGenAI”) that offers
AI-powered marketing software and robotic process automation (“RPA”) capabilities. By integrating AI-powered solutions and
RPA tools, Coeptis not only enhances its operational efficiency but also positions itself to leverage these advanced technologies for
broader applications, creating new opportunities for growth while maintaining its primary focus on biopharmaceutical innovation.
NexGenAI has developed a suite of innovative marketing tools that utilize
AI and RPA to optimize campaigns, streamline workflows, and generate actionable insights. By acquiring these assets, Coeptis will bring
these state-of-the-art solutions to companies seeking to overcome marketing challenges in competitive and highly regulated sectors, particularly
in the biotech, pharmaceutical and multi-level marketing (“MLM”) industries. These tools will help companies run smarter,
more efficient marketing campaigns, saving time and resources while staying compliant with strict regulations.
Dave Mehalick, President and CEO of Coeptis Therapeutics commented,
“We are excited to integrate NexGenAI Affiliates Network and groundbreaking AI and RPA-driven tools into our offerings. In industries
like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing,
streamline operations, and drive measurable results is critical.”
Anshuman Dash, Lead Advisory behind the development of NexGenAI Affiliates
Network commented, “The integration of NexGenAI's innovative AI-powered marketing solutions with Coeptis Therapeutics’ forward-thinking
approach marks a transformative step forward. This acquisition not only validates the cutting-edge technology we’ve developed but
also aligns with Coeptis’ mission to drive innovation in highly regulated industries. Together, we aim to revolutionize marketing
strategies and operational efficiencies, ultimately delivering greater value to our partners and the industries we serve."
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries
including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company
developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional
treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra
Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy
technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh
(SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical
researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio
and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic
partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered
in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary
suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software
and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven
insights. NexGenAI’s platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors.
By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth.
For more information on NexgenAI go to nexgenai.io.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection
therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans,
objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements
of historical facts. When we use words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely
to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance
and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from
our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to:
(1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration
of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated
benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and
manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed
assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5)
costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable
laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors;
and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking
statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained
in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place
undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made
or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking
statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
800-478-8070
v3.24.3
Cover
|
Dec. 03, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Dec. 03, 2024
|
Entity File Number |
001-39669
|
Entity Registrant Name |
COEPTIS THERAPEUTICS HOLDINGS, INC.
|
Entity Central Index Key |
0001759186
|
Entity Tax Identification Number |
98-1465952
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
105 Bradford Rd
|
Entity Address, Address Line Two |
Suite 420
|
Entity Address, City or Town |
Wexford
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
15090
|
City Area Code |
724
|
Local Phone Number |
934-6467
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock [Member] |
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
COEP
|
Security Exchange Name |
NASDAQ
|
Warrant [Member] |
|
Title of 12(b) Security |
Warrants,
each whole warrant exercisable for one-half of one share of Common Stock for $11.50 per whole share
|
Trading Symbol |
COEPW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Coeptis Therapeutics (NASDAQ:COEPW)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Coeptis Therapeutics (NASDAQ:COEPW)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024